Lin Shih-Yi, Won Justin Ging-Shing, Lee Tin-I, Tang Kam-Tsum, Lin Hong-Da
Department of Medicine, Taipei Veterans General Hospital, Taiwan, ROC.
Zhonghua Yi Xue Za Zhi (Taipei). 2002 Apr;65(4):156-63.
The corticotropin-releasing hormone (CRH) stimulation test is reliable for diagnosing pituitary or hypothalamic adrenal insufficiency. In the present study, we evaluated secondary adrenal insufficiency in patients with pituitary disease by CRH test and magnetic resonance imaging (MRI).
A total of 12 healthy persons and 20 patients with pituitary disorder were recruited, including 6 with Sheehan's syndrome, 6 with idiopathic panhypopituitarism, 3 with isolated ACTH deficiency, 2 with pituitary apoplexy, 2 with empty sella syndrome and I with postoperative suprasellar tumor. Blood ACTH and cortisol levels were measured after 100 microg ovine CRH (oCRH) intravenous bolus infusion.
In patients, basal ACTH was 15.9+/-17.3 pg/ml and basal cortisol was 4.8+/-4.6 microg/dl. These values were significantly lower than those in controls (p = 0.02). In 11 of 20 patients (3 with Sheehan's syndrome, 3 with panhypopituitarism, 2 with empty sella, 2 with isolated ACTH deficiency and 1 with pituitary apoplexy), a delayed and prolonged ACTH response was observed. In the other 9 patients, ACTH showed little change. In all patients, there was no apparent increase in cortisol value. Moreover this value was significantly lower than in healthy persons (6.2+/-5.4 vs. 21.1+/-6.0 microg/dl; p <0.0001). Sellar MRI showed complete empty change in all Sheehan's syndrome, apoplexy and empty sella syndrome patients. The six patients with panhypopituitarism had variable hypoplastic adenohypophysis with or without visible pituitary stalk. The three isolated ACTH deficiency cases demonstrated a normal anatomy.
Our study showed that patients with pituitary disease had significantly lower plasma cortisol response after oCRH than controls. Thus, CRH testing appears useful for the diagnosis of central adrenal insufficiency. The two different functional ACTH responses to CRH observed in each pituitary disorder did not correlate with damage levels shown on MRI.
促肾上腺皮质激素释放激素(CRH)刺激试验对于诊断垂体或下丘脑性肾上腺功能不全是可靠的。在本研究中,我们通过CRH试验和磁共振成像(MRI)评估垂体疾病患者的继发性肾上腺功能不全。
共招募了12名健康人和20名垂体疾病患者,包括6例席汉综合征患者、6例特发性全垂体功能减退患者、3例孤立性促肾上腺皮质激素(ACTH)缺乏患者、2例垂体卒中患者、2例空蝶鞍综合征患者和1例鞍上肿瘤术后患者。静脉推注100微克羊CRH(oCRH)后测量血ACTH和皮质醇水平。
患者的基础ACTH为15.9±17.3皮克/毫升,基础皮质醇为4.8±4.6微克/分升。这些值显著低于对照组(p = 0.02)。20例患者中有11例(3例席汉综合征、3例全垂体功能减退、2例空蝶鞍、2例孤立性ACTH缺乏和1例垂体卒中)观察到ACTH反应延迟且延长。在其他9例患者中,ACTH变化不大。所有患者的皮质醇值均无明显升高。此外,该值显著低于健康人(6.2±5.4对21.1±6.0微克/分升;p <0.0001)。蝶鞍MRI显示所有席汉综合征、垂体卒中和空蝶鞍综合征患者均有完全空蝶鞍改变。6例全垂体功能减退患者的腺垂体发育不全程度不一,有或无可见的垂体柄。3例孤立性ACTH缺乏病例的解剖结构正常。
我们的研究表明,垂体疾病患者oCRH后的血浆皮质醇反应显著低于对照组。因此,CRH试验似乎有助于诊断中枢性肾上腺功能不全。在每种垂体疾病中观察到的对CRH的两种不同功能性ACTH反应与MRI所示的损伤程度无关。